Dr. Amelie Gubitz joined the NINDS in 2006 and currently serves as a Program Director in the Neurodegeneration Cluster. Her portfolio includes basic, translational and clinical research on amyotrophic lateral sclerosis, X-linked spinal and bulbar muscular atrophy and hereditary spastic paraplegias. Dr. Gubitz earned a Ph.D. in pharmacology from the University of Cambridge, UK, and then completed a Wellcome Trust Fellowship at Harvard Medical School in circadian biology. Subsequently, she worked as a Senior Scientist in the target discovery group for neuropathic pain at Parke Davis, UK. In 2000, Dr. Gubitz joined the laboratory of Dr. Gideon Dreyfuss at the University of Pennsylvania where she studied the molecular pathogenesis of spinal muscular atrophy.
Last Modified March 9, 2015